Status: Recruiting
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
This is a phase l, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Participants needed: 30
Trial details
Phase: Phase 1Age: 2-70Biological sex: AllType: InterventionalSponsor: Nelson HamerschlakUpdated: Sep 25, 2025Locations: 1
Eligibility criteria
Subjects must have relapsed or refractory ALL, lymphoma or CLL treated with at l... [+7]
Autologous transplant within 6 weeks of planned CAR-T cell infusion; [+15]